About LYSOGENE

Company Description

Lysogeneโ€™s determination to succeed is rooted in our deep understanding of the impact central nervous system (CNS) diseases have on patients and families, and springs from our founder whose own child was affected by a neurodegenerative disease.

Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders.

Lysogene is a biopharmaceutical gene therapy company with lead programs in neurodegenerative lysosomal storage disorders that affect children.

Year founded

2009

Served area

Worldwide

Headcount

22

Headquarters

18-20 Rue Jacques Dulud, 92200 Neuilly-sur-Seine โ€“ France

Shareholder information

Shares outstanding

17,811,140

IPO

Feb. 8, 2017

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.